Latest Breaking News On - Potential additional - Page 1 : comparemela.com

More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 New Preclinical Data Showed OncoPLEX Injected Intratumorally Reduced Tumor Volume and Improved Survival in New Animal Models Recent Successful $16 Million Financing Extends Company’s Cash Runway

Ha afonDikla czaczkes akselbradBrian ritchieCzaczkes akselbradCompany annual report on formPolypid ltdFund polypidMore thanAbdominal colorectal surgical siteInterim analysisConducted once approximatelyComplete theirDay follow upTop line results expectedSecond halfIntratumorally reduced tumor volume